Skip to main content
OpenTrials
Completed

NCT Number: NCT04353388

Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Washington University

The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in earlier decision to administer antibiotics from time of ED presentation for sepsis patients (simulated primary endpoint), with concomitant reductions in length of stay and in-hospital mortality for those patients (secondary endpoints).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Washington University

St Louis, Missouri, 63110, United States

About this study

The objective of this study is to develop a method for identifying sepsis patients from electronic health records (EHR) based on Sepsis-2 criteria. Sepsis patients will be identified using a Sepsis Definition which includes meeting SIRS score of ≥2 within 12 hours of ED presentation and any microbial testing ordered within 24 hours of ED presentation. The patient will be enrolled if it meets the Sepsis Definition and additional EMR data elements will be extracted to complete case report form. Furthermore, objectives include to confirm the clinical validity and performance of MDW in a control population of sepsis patients where MDW is measured but not reported to physicians. This study is an observational study which will simulate the decision impact of MDW on sepsis identification and patient management

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All race and ethnicities
  • Presenting to the emergency department with suspicion of infection
  • Whose assessment includes a CBC with differential
  • Meets EMR Sepsis Definition

Exclusion criteria

  • Pregnancy
  • Prisoners
  • Transfers from other ED
  • Previously enrolled

Treatment and study plan

CBC-Diff Monocyte volume width distribution (MDW)

Diagnostic Test

MDW measurement will be used to detect sepsis. Results will not be used to manage patients.

Primary outcomes

  1. Potential reduction of Time to Antibiotics

    Time frame: 12 hours after ED presentation

    Validate MDW's ability to reduce time to first antibiotics ordered by physician (decision to treat)-Simulated

Secondary outcomes

  1. Performance

    Time frame: 12 hours after ED presentation

    Validate MDW's ability to identify incidence of patients diagnosed as Sepsis vs Non-Sepsis, including SIRS and milder forms of infection (non-SIRS) meeting Sepsis EMR definition of >=2 SIRS criteria within 12 hours of ED presentation and any microbial testing collected within 24 hours of triage in the ED

Other outcomes

  1. Health & Economic Benefits for Time to Antibiotics - Simulated

    Time frame: 12 hours after ED presentation

    Determine MDW's ability to potentially reduced hospital stay using a simulated economic model

  2. Health & Economic Benefits for Hospital Stay - Simulated

    Time frame: 12 hours after ED presentation

    Determine MDW's ability to potentially reduced Hospital stay, if applicable, using a simulated economic model

  3. Health & Economic Benefits for Mortality - Simulated

    Time frame: 12 hours after ED presentation

    Determine MDW's ability to potentially reduced hospital morality, if applicable, using a simulated economic model

  4. Health & Economic Benefits for ICU Stay - Simulated

    Time frame: 12 hours after ED presentation

    Determine MDW's ability to potentially reduced ICU stay, if applicable, using a simulated economic model

Sponsors and collaborators

Lead sponsor

Beckman Coulter, Inc.

Industry

Registry information

Official study title

Post Market Observational Study of ESId (MDW Hematology Parameter) for Early Sepsis Detection in the Emergency Department (US Hospitals) and Potential Reduction in Time to Antibiotics - Washington University

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 20, 2020
Registry last updated
Mar 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.